Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 977-985

  Tanaka, Akitaka ^a   Nakamura, Shigeki ^a   Seki, Masafumi ^b   Fukudome, Kenji ^c   Iwanaga, Naoki ^a   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Yanagihara, Katsunori ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY UT12; MONOCYTE CHEMOTACTIC PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOMODULATION; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; MALE; MIXED INFECTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PNEUMONIA; PRIORITY JOURNAL; SECONDARY INFECTION; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; BODY WEIGHT; COINFECTION; DISEASE MODELS, ANIMAL; HISTOCYTOCHEMISTRY; HUMANS; IMMUNITY, INNATE; MALE; MICE; MICE, INBRED C3H; MICE, INBRED CBA; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 4;

EID: 84880490876     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00010-13     Document Type: Article

References (37)

1. Mathers CD, Boerma T, Ma Fat D. 2009. Global and regional causes of death. Br. Med. Bull. 92:7-32.
2. Blyth CC, Webb SA, Kok J, Dwyer DE, van Hal SJ, Foo H, Ginn AN, Kesson AM, Seppelt I, Iredell JR; ANZIC Influenza Investigators; Microbiological Investigators COSI. 2012. The impact of bacterial and viral co-infection in severe influenza. Influenza Other Respi. Viruses 7:168-176.
3. McCullers JA. 2006. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19:571-582. (Pubitemid 44134311)
4. Brundage JF. 2006. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect. Dis. 6:303-312.
5. Morens DM, Taubenberger JK, Fauci AS. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198:962-970.
6. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, Hui J, Tokarz R, Briese T, Baumeister E, Lipkin WI. 2009. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 4:e8540. doi:10.1371/journal.pone.0008540.
7. Centers for Disease Control and Prevention (CDC). 2012. Severe coinfection with seasonal influenza A (H3N2) virus and Staphylococcus aureus - Maryland, February-March 2012. MMWR Morb. Mortal. Wkly. Rep. 61:289-291.
8. Cilloniz C, Ewig S, Menendez R, Ferrer M, Polverino E, Reyes S, Gabarrus A, Marcos MA, Cordoba J, Mensa J, Torres A. 2012. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J. Infect. 65:223-230.
9. Aebi T, Weisser M, Bucher E, Hirsch HH, Marsch S, Siegemund M. 2010. Co-infection of influenza B and streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect. Dis. 10:308. doi:10.1186/1471-2334-10-308.
10. Seki M, Yanagihara K, Higashiyama Y, Fukuda Y, Kaneko Y, Ohno H, Miyazaki Y, Hirakata Y, Tomono K, Kadota J, Tashiro T, Kohno S. 2004. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur. Respir. J. 24:143-149. (Pubitemid 39029080)
11. Boivin N, Sergerie Y, Rivest S, Boivin G. 2008. Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis. J. Infect. Dis. 198:664-672.
12. Lin YS, Huang LD, Lin CH, Huang PH, Chen YJ, Wong FH, Lin CC, Fu SL. 2011. In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator. J. Biol. Chem. 286:43782-43792.
13. Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, Chu Y. 2011. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol. 186:1963-1969.
14. Jarchum I, Liu M, Lipuma L, Pamer EG. 2011. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect. Immun. 79:1498-1503.
15. Ohta S, Bahrun U, Shimazu R, Matsushita H, Fukudome K, Kimoto M. 2006. Induction of long-term lipopolysaccharide tolerance by an agonistic monoclonal antibody to the toll-like receptor 4/MD-2 complex. Clin. Vaccine Immunol. 13:1131-1136. (Pubitemid 44622541)
16. St Paul M, Mallick AI, Read LR, Villanueva AI, Parvizi P, Abdul- Careem MF, Nagy E, Sharif S. 2012. Prophylactic treatment with Tolllike receptor ligands enhances host immunity to avian influenza virus in chickens. Vaccine 30:4524-4531.
17. Clement CG, Evans SE, Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, Dickey BF, Tuvim MJ. 2008. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177: 1322-1330. (Pubitemid 351860909)
18. Kosai K, Seki M, Tanaka A, Morinaga Y, Imamura Y, Izumikawa K, Kakeya H, Yamamoto Y, Yanagihara K, Tomono K, Kohno S. 2011. Increase of apoptosis in a murine model for severe pneumococcal pneumonia during influenza A virus infection. Jpn. J. Infect. Dis. 64:451-457.
19. Yanagihara K, Seki M, Cheng PW. 2001. Lipopolysaccharide induces mucus cell metaplasia in mouse lung. Am. J. Respir. Cell Mol. Biol. 24:66-73. (Pubitemid 32097509)
20. Jordan MB, van Rooijen N, Izui S, Kappler J, Marrack P. 2003. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 101:594-601. (Pubitemid 36077582)
21. Matsuda N, Hattori Y. 2006. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. J. Pharmacol. Sci. 101:189-198. (Pubitemid 44114312)
22. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M, Kawaoka Y, Rosen H, Oldstone MB. 2011. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl. Acad. Sci. U. S. A. 108:12018-12023.
23. Liu SF, Malik AB. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 290:L622-L645. (Pubitemid 43738989)
24. Chao J, Blanco G, Wood JG, Gonzalez NC. 2011. Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia. Am. J. Physiol. Heart Circ. Physiol. 301:H2264-H2270.
25. van Rooijen N, van Kesteren-Hendrikx E. 2002. Clodronate liposomes: perspectives in research and therapeutics. J. Liposome Res. 12:81-94.
26. Yu FS, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, Gao N, Yoon SG, Gallo RL, Standiford TJ. 2010. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J. Immunol. 185:1142-1149.
27. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13:552-559. (Pubitemid 46830615)
28. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M. 2011. Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice. FEMS Immunol. Med. Microbiol. 63:407-417.
29. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER. 2011. The Toll-like receptor 4 agonist monophosphoryl lipid A augments innate host resistance to systemic bacterial infection. Infect. Immun. 79: 3576-3587.
30. Akira S, Sato S. 2003. Toll-like receptors and their signaling mechanisms. Scand. J. Infect. Dis. 35:555-562. (Pubitemid 37336872)
31. Winter C, Herbold W, Maus R, Langer F, Briles DE, Paton JC, Welte T, Maus UA. 2009. Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J. Immunol. 182:4931-4937.
32. Winter C, Taut K, Srivastava M, Langer F, Mack M, Briles DE, Paton JC, Maus R, Welte T, Gunn MD, Maus UA. 2007. Lung-specific over-expression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J. Immunol. 178:5828-5838. (Pubitemid 46674380)
33. Lehner MD, Ittner J, Bundschuh DS, van Rooijen N, Wendel A, Hartung T. 2001. Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar Typhimurium infection despite attenuated cytokine response. Infect. Immun. 69:463-471. (Pubitemid 32038345)
34. Dessing MC, Hirst RA, de Vos AF, van der Poll T. 2009. Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice. PLoS One 4:e7993. doi:10.1371/journal.pone.0007993.
35. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U. S. A. 100: 1966-1971. (Pubitemid 36254557)
36. De Nardo D, De Nardo CM, Nguyen T, Hamilton JA, Scholz GM. 2009. Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages. J. Immunol. 183: 8110-8118.
37. Lim JH, Ha U, Sakai A, Woo CH, Kweon SM, Xu H, Li JD. 2008. Streptococcus pneumoniae synergizes with nontypeable Haemophilus influenzae to induce inflammation via upregulating TLR2. BMC Immunol. 9:40. doi:10.1186/1471-2172-9- 40.